Highbridge Capital Management’s Emergent Biosolutions EBS Stock Holding History

Highbridge Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-45,600	Closed	-$1.32M	–	1334
2017 Q1	$1.32M	Buy	45,600 +32,937	+260%	+$1M	0.02%	533
2016 Q4	$416K	Buy	+12,663	New	+$380K	0.01%	843
2016 Q2	–	Sell	-9,991	Closed	-$363K	–	1485
2016 Q1	$363K	Sell	9,991 -33,167	-77%	-$1.17M	0.01%	1105
2015 Q4	$1.73M	Buy	+43,158	New	+$1.5M	0.03%	569
2014 Q4	–	Sell	-13,027	Closed	-$278K	–	1233
2014 Q3	$278K	Sell	13,027 -24,075	-65%	-$551K	﹤0.01%	1025
2014 Q2	$833K	Buy	37,102 +8,189	+28%	+$191K	0.01%	608
2014 Q1	$731K	Sell	28,913 -21,186	-42%	-$535K	0.01%	620
2013 Q4	$1.15M	Buy	+50,099	New	+$1.04M	0.01%	500

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Highbridge Capital Management's EBS Position: Q2 2017 in Review

Highbridge Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2017, closing a stake of 45,600 shares — an estimated $1.32M sold.

Highbridge Capital Management first reported a position in EBS in Q4 2013 and held it in 8 quarters. The position peaked at $1.73M in Q4 2015. 181 funds tracked by Wall St. Rank hold EBS as of Q2 2017.

Highbridge Capital Management reported no remaining Emergent Biosolutions position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 45,600 Emergent Biosolutions shares in Q2 2017, an estimated $1.32M.
Highbridge Capital Management first reported a position in Emergent Biosolutions in Q4 2013 and held it in 8 quarters.
Highbridge Capital Management's Emergent Biosolutions position peaked at $1.73M in Q4 2015.
181 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.